Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection

PURPOSE: Bevacizumab plus fluoropyrimidine-based chemotherapy is standard treatment for first-line and second-line metastatic colorectal cancer (mCRC). However, to date, there is no current biomarker predictive for the benefit of bevacizumab use for these patients. Preclinical data suggest that the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghiringhelli, Francois, Bichard, Damien, Limat, Samuel, Lorgis, Veronique, Vincent, Julie, Borg, Christophe, Berthou, Julie, Orry, David, Ortega-Deballon, Pablo, Lakkis, Zaher, Facy, Olivier, Heyd, Bruno, Rat, Patrick, Nerich, Virginie, Ladoire, Sylvain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Colorectal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975091/
https://www.ncbi.nlm.nih.gov/pubmed/24419756
http://dx.doi.org/10.1245/s10434-013-3463-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975091/
https://www.ncbi.nlm.nih.gov/pubmed/24419756
http://dx.doi.org/10.1245/s10434-013-3463-y

Ejemplares similares